Search

Your search keyword '"Liu, Zhaoyun"' showing total 490 results
Start Over Author "Liu, Zhaoyun"
490 results on '"Liu, Zhaoyun"'

106. Self-assembly of X-shaped antibody to combine the activity of IgG and IgA for enhanced tumor killing

Author

Liang, Yuexia, primary, Li, Xin, additional, Peng, Fengping, additional, Ye, Xiaohan, additional, Wang, Wei, additional, Cen, Tianyi, additional, Li, Fan, additional, Lu, Yue, additional, Liu, Zhaoyun, additional, Liu, Hui, additional, Ding, Kai, additional, Ye, Kai, additional, Yu, Yang, additional, Ma, Tianyu, additional, Zhang, Sihe, additional, Huang, Yi, additional, Wang, Yuan, additional, Yang, Xue, additional, Fu, Rong, additional, and Zhang, Hongkai, additional

Published
2022
Full Text
View/download PDF

107. Case Report: Sirolimus Alleviates Persistent Cytopenia After CD19 CAR-T-Cell Therapy

Author

Xing, Limin, Wang, Yihao, Liu, Hui, Gao, Shan, Shao, Qing, Yue, Lanzhu, Liu, Zhaoyun, Wang, Huaquan, Shao, Zonghong, and Fu, Rong

Subjects
Cancer Research, sirolimus, Oncology, CD19, hemic and lymphatic diseases, diffuse large B-cell lymphoma, cytopenia, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Case Report, chimeric antigen receptor T cell, RC254-282
Abstract

Chimeric antigen receptor T (CAR-T) cells show good efficacy in the treatment of relapsed and refractory B-cell tumors, such as acute B-cell leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). The main toxicities of CAR-T include cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, cytopenia, and severe infection. It is still very difficult for CAR-T to kill tumor cells to the maximum extent and avoid damaging normal organs. Here, we report a case of DLBCL with persistent grade 4 thrombocytopenia and severe platelet transfusion dependence treated with CD19 CAR-T cells. We used sirolimus to inhibit the sustained activation of CAR-T cells and restore normal bone marrow hematopoiesis and peripheral blood cells. Moreover, sirolimus treatment did not affect the short-term efficacy of CAR-T cells, and DLBCL was in complete remission at the end of follow-up. In conclusion, sirolimus can represent a new strategy for the management of CAR-T cell therapy-related toxicity, including but not limited to hematotoxicity. However, further controlled clinical studies are required to confirm these findings.

Published
2021

116. Clinical observation of low-dose combination chemotherapy in refractory/recurrent paroxysmal nocturnal hemoglobinuria patients: a single-centre retrospective analysis

Author

Li, Liyan, primary, Liu, Hui, additional, Wang, Honglei, additional, Liu, Zhaoyun, additional, Chen, Yingying, additional, Liu, Chunyan, additional, Zhao, Xiaoyu, additional, Li, Lijuan, additional, Wang, Huaquan, additional, Shao, Zonghong, additional, and Fu, Rong, additional

Published
2021
Full Text
View/download PDF

120. Deferasirox combination with eltrombopag shows anti-myelodysplastic syndrome effects by enhancing iron deprivation-related apoptosis.

Author

Lei Huang, Mengyue Tian, Zhaoyun Liu, Chunyan Liu, Rong Fu, Huang, Lei, Tian, Mengyue, Liu, Zhaoyun, Liu, Chunyan, and Fu, Rong

Subjects
MYELODYSPLASTIC syndromes, RESEARCH, HETEROCYCLIC compounds, IRON, ORGANIC compounds, IRON in the body, CHELATING agents, APOPTOSIS, ANTI-infective agents, EVALUATION research, COMPARATIVE studies, RESEARCH funding, THROMBOCYTOPENIA, PHARMACODYNAMICS, DISEASE complications
Abstract

Iron overload (IO) affected the survival of patients with myelodysplastic syndrome (MDS). Deferasirox (DFX) is widely used in patients with MDS for iron chelation therapy, but is not suitable for MDS patients with severe thrombocytopenia. Eltrombopag (ELT) is a type of thrombopoietin receptor (TPOR) analog used in the treatment of thrombocytopenia. Therefore, we sought to explore the synergistic effects and possible mechanisms of DFX combination with ELT in MDS cells. In our study, the combination of DFX with ELT synergistically inhibited proliferation, induced apoptosis and arrested cell cycle of MDS cells. Through the RNA-sequence and gene set enrichment analysis (GSEA), iron metabolism-related pathway played important roles in apoptosis of SKM-1 cells treated with DFX plus ELT. Transferrin receptor (TFRC) was significantly highly expressed in combination group than that in single agent groups, without affecting TPOR. Furthermore, the apoptosis of the combination group MDS cells could be partially reversed by ferric ammonium citrate (FAC), accompanied with decreased expression of TFRC. These results suggested that the combination of DFX and ELT synergistically induced apoptosis of MDS cells by enhancing iron deprivation-related pathway. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

129. EGFR Promotes the Development of Triple Negative Breast Cancer Through JAK/STAT3 Signaling

Author

Song,Xiang, Liu,Zhaoyun, and Yu,Zhiyong

Subjects
Cancer Management and Research
Abstract

Xiang Song,1 Zhaoyun Liu,1,2 Zhiyong Yu1 1Department of Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, Shandong, People’s Republic of China; 2School of Medicine, Shandong University, Jinan, People’s Republic of ChinaCorrespondence: Zhiyong YuDepartment of Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, 440 Jiyan Road, Jinan 250117, Shandong, People’s Republic of ChinaEmail drzhiyongyu@aliyun.comPurpose: To investigate the role of EGFR and STAT3 in breast cancer development and progression.Methods: Through bioinformatics analysis differently expressed genes (DEGs) including EGFR and STAT3 were identified in breast cancer tissue. QRT-PCR and Western blot analysis were used to investigate EGFR and STAT3 levels in breast cancer tissues and cells. The influence of EGFR and STAT3 on the breast cancer cell proliferation (CCK-8 assay, clone formation assays), migration (wound healing assays) and invasion (transwell assays) were investigated. The influence of EGFR on breast cancer in vivo was examined by Nude mouse transplantation tumor experiments and immunohistochemistry (IHC) staining. The effects of EGFR on breast cancer signaling were assessed via Western blot.Results: Both EGFR and p-STAT3 were up-regulated in breast cancer tissues and cell lines. EGFR expression was positively associated with p-STAT3. Moreover, EGFR and p-STAT3 activity enhanced the proliferation and invasion of tumor cells. Breast cancer cell growth was dramatically inhibited by EGFR silencing in vivo.Conclusion: EGFR promotes breast cancer progression via STAT3 phosphorylation and JAK/STAT3 signaling.Keywords: EGFR, STAT3, p-STAT3, breast cancer

Published
2020

150. Immune profiles to predict bortezomib-based treatment response for multiple myeloma patients.

Author

Liu, Zhaoyun, Shen, Hongli, Han, Mei, Zhao, Xianghong, Liu, Hui, Ding, Kai, Song, Jia, and Fu, Rong

Subjects
*B cells, *MULTIPLE myeloma, *PLASMA cells, *BONE marrow cells, *LYMPHOCYTE subsets, *IMMUNOLOGIC memory
Abstract

• In our study, eight-color flow cytometry, a method commonly used to detect plasma cell phenotypes, was used to analyze seven bone marrow immune cell groups by change gate-strategy. • We found that the analysis of lymphocyte subsets along with plasma cell immunophenotyping could be a potential index for determining the prognosis of patients with MM. To evaluate the distribution of bone marrow immune cell subsets and their correlation with treatment efficacy in patients with multiple myeloma (MM). We analyzed the bone marrow lymphocyte subsets of 186 newly diagnosed MM patients at diagnosis and their correlation with clinical characteristics. In our study, eight-color flow cytometry, a method commonly used to detect plasma cell phenotypes, was used to analyze seven bone marrow immune cell groups by change gate-strategy. First, for all the 7 immune cell groups, the percentage of immature B cells was significantly lower in stage III patients than in stage I patients, while the trend was reversed in memory B cells in both the International Staging System(p = 0.004) and Revised International Staging System(p = 0.018). Second, the percentage of naïve B cells were significantly lower in patients with severe anemia, while the percentage of memory B cells had reversed trend. The percentage of immature B cells were lower in patients with Cr ≥ 2 mg/dL than in patients with Cr < 2 mg/dL. Then we followed the treatment efficacy of 152 patients who received four cycles of induction therapy (bortezomib + dexamethasone or bortezomib + lenalidomide + dexamethasone) and analyzed the relationship between bone marrow lymphocyte subsets at the initial stage and treatment response datasets. We found that both the percentage of B cells(p ＜0.001) and immature B(p = 0.002) were increased in patients who achieved very good partial remission(VGPR) after four cycles of induction therapy. The ROC results indicated the combination of the multiple immune subgroups had predictive values (AUC = 0.802, p <0.001) in the treatment effect after four cycles of induction therapy. Overall, these results suggest that the analysis of lymphocyte subsets along with plasma cell immunophenotyping could be a potential index for determining the prognosis of MM patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results